Biotech firm Nkarta posts Q2 net loss; cash runway into 2029

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell".

The average consensus recommendation for the biotechnology & medical research peer group is "buy".

Wall Street's median 12-month price target for Nkarta, Inc. is $11.00, about 356.4% above its August 7 closing price of $2.41.

Enrollment continues in Ntrust-1 and Ntrust-2 trials, with initial data expected in 2026.

Nkarta said it continued to enroll patients in the Ntrust-1 and Ntrust-2 trials at the 4 billion cell dose level across all indications. Outpatient dosing of NKX019 began at community-based sites, broadening patient access beyond academic centers.

The trials are designed to assess NKX019 as a single agent without supplemental cytokines or antibody-based therapeutics.